CD8A and plasma cell myeloma: CD8+ T cells transduced with JCHAIN-specific T cell receptors (TCRs) demonstrated potent in vitro and in vivo killing activity against multiple myeloma, confirming JCHAIN’s potential as an immunotherapeutic target [36].